Alcoholic liver disease is getting a new name, alcohol-associated liver disease, or AALD. The disease is also getting new treatment approaches and new attention from researchers, clinicians and industry, according to Gyongyi Szabo, MD, PhD, FAASLD.
The management of cirrhosis has evolved at a rapid pace in recent years. During a case-based AASLD symposium on the final day of DDW® 2018, three experts reviewed the most recent developments in diuretic resistant/refractory ascites, recurrent/refractory hepatic encephalopathy and recurrent/refractory variceal bleeding. The panel was co-moderated by Catherine Frenette, MD, FAST, AGAF.
The addictive nature of opioids and the increasing number of overdoses and fatalities in America has been intensively researched and publicized, but there has been
Nonalcoholic fatty liver disease (NAFLD), which is strongly linked to diabetes, high cholesterol and heart disease, has become increasingly common around the world, especially in
The AASLD Clinical Symposium HCV Treatment: Gastroenterologists Role in Eradicating HCV featured a panel of experts who discussed strategies to maximize the number of individuals who are treated for chronic HCV. “Despite recommendations and, in some states, mandates, we are falling behind on HCV screening,” said Robert S. Brown Jr., MD, MPH, AGAF.
Kathleen E. Corey, MD, MPH, MMSc, will deliver “Challenges in Screening for NAFLD (Including At-Risk Populations)” during Clinical Challenges in Adult and Pediatric Non-Alcoholic Fatty Liver Disease on Monday.
Patrick S. Kamath, MD, DM, MBBS, will define acute-on-chronic liver failure and review its history and scope during Monday’s AASLD State-of-the-Art Lecture Acute on Chronic Liver Failure: Pathophysiology and Therapeutic Approach.
Although antiviral therapy has led to a cure rate of more than 90 percent of hepatitis C virus (HCV) cases, David E. Bernstein, MD, FAASLD, thinks more can be done to increase the cure rate. In this DDW Daily News video exclusive, Dr. Bernstein discusses several obstacles preventing patients’ access to curative therapies. He also addresses the benefits of HCV therapy and whether it’s possible to eradicate HCV and achieve 100 percent cure rate.
During Sunday’s AASLD State-of-the-Art Lecture Evolving Management of Cholestatic Liver Diseases, Cynthia Levy, MD, FAASLD, will discuss the treatment of primary biliary cholangitis and primary sclerosing cholangitis, the two most common causes of chronic cholestatic liver disease in adults.
AASLD will feature the most innovative research in its two plenary sessions at DDW®, according to AASLD President Ronald J. Sokol, MD, FAASLD. The Basic Science Plenary Session will be held Sunday morning and the Clinical Science Plenary Session will be held Monday morning. Each will offer something for all AASLD members and DDW attendees.
